Table 2.

Characteristics of cancer patients grouped according to seroconversion outcome.

	Not seroconverted (N = 10)	Seroconverted (N = 161)	p
Age (SD)	67.24 (7.88)	64.99 (11.62)	0.548
Gender, female (%)	5 (50.0)	96 (59.6)	0.788
BMI (SD)	27.27 (4.71)	69.45 (4.44)	0.132
Smoking history (%)
Never	5 (50.0)	104 (64.6)	0.586
Active	3 (30.0)	39 (24.2)
Former	2 (20.0)	18 (11.2)
Steroid therapy (%)
None	9 (90.0)	133 (82.6)	0.780
<10 mg of prednisone	1 (10.0)	23 (14.3)
≥10 mg of prednisone	0 (0.0)	5 (3.1)
ECOG PS (%)
0–2	8 (80.0)	157 (97.5)	0.001
>2	2 (20.0)	4 (2.5)
Lymphocytes before first dose/mm3 (SD)	1484.33 (441.81)	1728.05 (1118.82)	0.515
Lymphocytes before second dose/mm3 (SD)	1567.00 (535.46)	1691.61 (753.77)	0.608
Tumour primary (%)
Colorectal cancer	3 (30.0)	39 (24.2)	1.000
Breast cancer	2 (20.0)	34 (21.1)
Non-small cell lung cancer	3 (30.0)	24 (14.9)
Ovarian cancer	0 (0.0)	13 (8.1)
Pancreatic cancer	1 (10.0)	11 (6.8)
Stomach cancer	1 (10.0)	11 (6.8)
Others	0 (0.0)	29 (18.1)
Stage (%)
Locally advanced	2 (20.0)	31 (19.3)	0.782
Metastatic	8 (80.0)	130 (80.7)
Context of cancer treatment, palliative (%)	8 (80.0)	134 (83.2)	1.000
Anticancer agents (%)
ChT	8 (80.0)	102 (63.4)	0.468
IOT	1 (10.0)	22 (13.7)	1.000
TT	5 (50.0)	73 (45.3)	1.000
Neutralising Ab % (SD)	20.27% (14.28)	76.16% (24.64)	<0.001

Keys. Ab = antibodies; BMI = body mass index; ChT = cytotoxic chemotherapy; ECOG = Eastern Cooperative Oncology Group; IOT = immune checkpoint inhibitor immunotherapy; N = numerosity; NA = not applicable; PS = performance status; SD = standard deviation; TT = targeted therapy.

All continuous variables (age, BMI, lymphocytes before first and second dose, and neutralising antibodies) are reported as mean.